The potential of tumour mechanotargeting in lung cancer therapeutics

被引：1
作者：
Papavassiliou, Kostas A. [1 ]
Gargalionis, Antonios N. [2 ]
Papavassiliou, Athanasios G. [3 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Univ Dept Resp Med 1, Sotiria Chest Hosp, Med Sch, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Med Sch, Lab Clin Biochem, Athens, Greece
[3] Natl & Kapodistrian Univ Athens, Med Sch, Dept Biol Chem, Athens, Greece
来源：
PULMONOLOGY | 2025年 / 31卷 / 01期
关键词：
Lung cancer; mechanobiology; extracellular matrix; tumour microenvironment; cancer-associated fibroblasts; MATRIX STIFFNESS; DOUBLE-BLIND; NINTEDANIB; PLACEBO;
D O I：
10.1080/25310429.2024.2411808
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1 / 4
页数：4
相关论文
共 20 条
[1]   YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [J].
Chen, Peixin ;
Sun, Chenglong ;
Wang, Hao ;
Zhao, Wencheng ;
Wu, Yan ;
Guo, Haoyue ;
Zhou, Caicun ;
He, Yayi .
CELL DEATH & DISEASE, 2023, 14 (09)
[2]   Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer [J].
Cords, Lena ;
Engler, Stefanie ;
Haberecker, Martina ;
Ruschoff, Jan Hendrik ;
Moch, Holger ;
de Souza, Natalie ;
Bodenmiller, Bernd .
CANCER CELL, 2024, 42 (03) :396-412.e5
[3]   The matrix in cancer [J].
Cox, Thomas R. .
NATURE REVIEWS CANCER, 2021, 21 (04) :217-238
[4]   Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling [J].
Graham, Keith ;
Lienau, Philip ;
Bader, Benjamin ;
Prechtl, Stefan ;
Naujoks, Jan ;
Lesche, Ralf ;
Weiske, Joerg ;
Kuehnlenz, Julia ;
Brzezinka, Krzysztof ;
Potze, Lisette ;
Zanconato, Francesca ;
Nicke, Barbara ;
Montebaur, Anna ;
Bone, Wilhelm ;
Golfier, Sven ;
Kaulfuss, Stefan ;
Kopitz, Charlotte ;
Pilari, Sabine ;
Steuber, Holger ;
Hayat, Sikander ;
Kamburov, Atanas ;
Steffen, Andreas ;
Schlicker, Andreas ;
Buchgraber, Philipp ;
Braeuer, Nico ;
Font, Nuria Aiguabella ;
Heinrich, Tobias ;
Kuhnke, Lara ;
Nowak-Reppel, Katrin ;
Stresemann, Carlo ;
Steigemann, Patrick ;
Walter, Annette O. ;
Blotta, Simona ;
Ocker, Matthias ;
Lakner, Ashley ;
von Nussbaum, Franz ;
Mumberg, Dominik ;
Eis, Knut ;
Piccolo, Stefano ;
Lange, Martin .
CELL CHEMICAL BIOLOGY, 2024, 31 (07) :1247-1263.e16
[5]   Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial [J].
Hanna, Nasser H. ;
Kaiser, Rolf ;
Sullivan, Richard N. ;
Aren, Osvaldo Rudy ;
Ahn, Myung-Ju ;
Tiangco, Beatrice ;
Voccia, Isabelle ;
von Pawel, Joachim ;
Kovcin, Vladimir ;
Agulnik, Jason ;
Gaschler-Markefski, Birgit ;
Barrueco, Jose ;
Sikken, Patricia ;
Schloss, Charles ;
Kim, Joo-Hang .
LUNG CANCER, 2016, 102 :65-73
[6]   Extracellular matrix and its therapeutic potential for cancer treatment [J].
Huang, Jiacheng ;
Zhang, Lele ;
Wan, Dalong ;
Zhou, Lin ;
Zheng, Shusen ;
Lin, Shengzhang ;
Qiao, Yiting .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[7]   Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis [J].
Irvine, Andrew F. ;
Waise, Sara ;
Green, Edward W. ;
Stuart, Beth ;
Thomas, Gareth J. .
SCIENTIFIC REPORTS, 2021, 11 (01)
[8]   The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer [J].
Jiang, Yu ;
Xie, Wen-Jing ;
Chen, Rong-Wei ;
You, Wei-Wei ;
Ye, Wei-Lin ;
Chen, Hong ;
Chen, Wen-Xu ;
Xu, Jian-Ping .
FRONTIERS IN SURGERY, 2022, 9
[9]   Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers [J].
Liang, Hongge ;
Xu, Yan ;
Zhao, Jing ;
Chen, Minjiang ;
Wang, Mengzhao .
CANCER GENE THERAPY, 2024, 31 (05) :652-666
[10]   YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting [J].
Lo Sardo, Federica ;
Strano, Sabrina ;
Blandino, Giovanni .
CANCERS, 2018, 10 (05)
12